| 
Latest News & Publications
Mycosynthetix, Inc has been awarded two Therapeutic Discovery Project Grants by the IRS. The grants are for projects that "showed significant potential to produce new and cost-saving therapies, support jobs and increase U.S. competitiveness." More information is available on the IRS website.
The grants were awarded for the following projects:
New Antibiotics for TB from Unusual Fungi
New Cancer Medicines from Unusual Fungi
November, 2010— Mycosynthetix CEO, Dr. Cedric Pearce, is giving a talk entitled Traditional and Modern Medicines from Fungi at New Developments in Drug Discovery from Natural Products and Traditional Medicines (DDNPTM 2010) and the International Conference on Folk and Herbal Medicine (ICFHM 2010) in India.
'New Developments in Drug Discovery from Natural Products and Traditional Medicines' at S.A.S. Nagar, Punjab, India from
November 20 to 24, 2010
'International conference on Folk and Herbal Medicine' at Udaipur (Rajasthan), India from November 25 to 27, 2010
To arrange a meeting with Dr. Pearce while he is in India, please contact him at cpearce@mycosynthetix.com.
Mycosynthetix CEO, Dr. Cedric Pearce, and colleagues presented at the 51st Annual Meeting of the American Society of Pharmacognosy in Tampa, Florida this July. Their presentation focused on the antimalarial compounds which have been discovered within microorganisms, such as the fungi in the Mycosynthetix library.
Ryan Baker, Anthony Nguyen, Jacqueline Salm, Charles Harter, Matt Lebar,
Laurent Calcul, Jeremy Beau, Jaime H. Noguez, Raymond Chow, Tina Mutka,
Dennis Kyle, Alberto Van Olphen, Cedric Pearce, Lilian Vrijmoed, Ka-Lai
Pang, Bill Baker. Antimalarial Constituents of Microorganisms. The 51st
Annual Meeting of the American Society of Pharmacognosy, Tampa, Florida.
July, 2010
Shortly after the posting of this release, Verenium's biofuels division was acquired by British Petroleum. Mycosynthetix' contract has been transferred to BP in the exchange.
Read the full release.
Mycosynthetix, Inc. was recently awarded a Phase I
Small Business Innovation Research grant from the National Institutes of Allergy and Infectious Diseases for the project
New Tuberculosis Antibiotics from Filamentous Fungi.
Read the full release.
Mycosynthetix is currently developing Mevalocidin, a new herbicidal
natural product from fungal fermentation, for use in organic farming. The
US Patent for Mevalocidin (pdf) was issued on July
1st, 2008. Dow AgroSciences LLC of Indianapolis and Mycosynthetix Inc have
entered into a royalty-bearing agreement for Mycosynthetix to develop and
market this herbicide.
Contact Dr. Cedric Pearce, CEO, at cpearce@mycosynthetix.com for further information.
Mycosynthetix has a number of fungi which are
active against this deadly organism. For example see the following
article:
Christie Boros, Alissa Dix, Barry Katz, Yelena Vasina
and Cedric Pearce: Isolation and Identification of Cissetin - A
Setin-like Antibiotic with a Novel cis-Octalin Ring Fusion. Journal
of Antibiotics 56, 862-5 (2003).
Mycosynthetix has a number of fungi which have shown activity against influenza targets.
For example see the following article:
The structure of a new antiviral product isolated from
a fungus from the Mycosynthetix collection was recently published:
see Emmyguyacins A and B: Unusual Glycolipids from a Sterile Fungus
Species that Inhibit the Low-pH Conformational Change of Hemagglutinin
A during Replication of Influenza Virus. Christie Boros, Barry Katz,
Scott Mitchell, Cedric Pearce, Karra Swinbeck and Debra Taylor, J.
Natural Products, 65, 108-114 (2002).
Mycosynthetix fungi have been investigated for low molecular weight gene modulators
and a number of interesting compounds found. For example see the following
anti-diabetic compound:
A potential anti-diabetic compound has been discovered from a Mycosynthetix
fungus and is described in the following publication: Chaowei Zhang,
Liang Lin, Belinda Mondie, Scott Mitchell, Arlindo Castelhano, Weizhong
Cai and Nils Bergenhem: Leporin B: A Novel Hexokinase II Gene Inducing
Agent from an Unidentified Fungus. Bioorganic and Medicinal Chemistry
Letters 13 (2003) 1433-1435.
Home : :
Science & Technology : :
Current Projects
News & Publications : :
About Us : : Contact
|
